Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to tame high potassium in kidney patients with standardized care

NCT ID NCT06884267

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 4 times

Summary

This study tests whether a standardized care plan can help chronic kidney disease patients better control high potassium levels while optimizing their RAASi medications. About 1,000 participants will receive the care plan, which includes doctor training and patient education. The main goal is to see if more patients achieve normal potassium levels and optimal medication use after 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
standardized hyperkalemia management implementation (clinical pathway and education)
What this could lead to
If successful, this could establish a practical, guideline-based care approach to help kidney disease patients better manage high potassium levels while optimizing their heart-kidney protective medications.
What could go wrong
This is an early-stage, single-arm study without a comparison group, so results may not prove the approach is better than usual care. Success depends on real-world adherence and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,000 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years, at the time of signing the informed consent. 2. HK (sK+ \> 5.0 mmol/L) within 48 hours before enrolment. 3. Patients diagnosed as chronic kidney disease with eGFR\>10 ml/min/1.73m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation (2021). See 8.3.4 for detailed equation. 4. Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Exclusion Criteria: 1. Patients on dialysis. 2. Pseudohyperkalemia signs and symptoms, such as hemolyzed blood specimen due to excessive fist clenching to make veins prominent, difficult or traumatic venipuncture, or history of severe leukocytosis or thrombocytosis. 3. Patients with acute kidney injury (AKI) or diabetic ketoacidosis (DKA). 4. Patients with cardiac arrhythmias that require immediate treatment 5. Patients scheduled for renal transplant or with a history of renal transplant. 6. Life expectancy \< 48 weeks. 7. History of malignancy except for: 7.1 Malignancy treated with curative intent and with no known active disease within 3 years before the enrolment and of low potential risk for recurrence. 7.2 Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease. 7.3 Adequately treated carcinoma in situ without evidence of disease. 8. Be participating in other intervention clinical trials. 9. Judgment by the HCP that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (non-dialysis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease Hyperkalemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperkalemia

Contacts and locations

Locations

  • Research Site

    Beijing, 100029, China

  • Research Site

    Benxi, 117000, China

  • Research Site

    Changchun, 130041, China

  • Research Site

    Changsha, 410008, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Changsha, 410300, China

  • Research Site

    Chengdu, 610031, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chengdu, 610078, China

  • Research Site

    Chongqing, 400042, China

  • Research Site

    Dalian, 116023, China

  • Research Site

    Fuyang, 236600, China

  • Research Site

    Fuzhou, 350005, China

  • Research Site

    Fuzhou, 350031, China

  • Research Site

    Gejiu, 661099, China

  • Research Site

    Guangzhou, 510280, China

  • Research Site

    Guangzhou, 510530, China

  • Research Site

    Guiyang, 510630, China

  • Research Site

    Haikou, 570311, China

  • Research Site

    Hangzhou, 310006, China

  • Research Site

    Hefei, 230001, China

  • Research Site

    Hohhot, 10050, China

  • Research Site

    Jinan, 250012, China

  • Research Site

    Jinan, 250021, China

  • Research Site

    Kunming, 650021, China

  • Research Site

    Kunming, 650101, China

  • Research Site

    Lanzhou, 730030, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nanning, 530021, China

  • Research Site

    Nantong, 226001, China

  • Research Site

    Ningbo, 315010, China

  • Research Site

    Pingdingshan, 467000, China

  • Research Site

    Qiqihar, 161000, China

  • Research Site

    Shanghai, 200025, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Shanghai, 200233, China

  • Research Site

    Shenyang, 110001, China

  • Research Site

    Shijiazhuang, 50051, China

  • Research Site

    Taiyuan, 030001, China

  • Research Site

    Tianjin, 300192, China

  • Research Site

    Ürümqi, 830054, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhu, 241000, China

  • Research Site

    Wuxi, 214062, China

  • Research Site

    Xi'an, 710061, China

  • Research Site

    Xining, 810001, China

  • Research Site

    Xinxiang, 453100, China

  • Research Site

    Yinchuan, 750004, China

  • Research Site

    Zhengzhou, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.